- Home
- HPH vs PLX Comparison
HPH vs PLX Comparison
Compare HPH & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPH
- PLX
- Stock Information
- Founded
- HPH 2010
- PLX 1993
- Country
- HPH China
- PLX Israel
- Employees
- HPH N/A
- PLX N/A
- Industry
- HPH
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HPH
- PLX Health Care
- Exchange
- HPH NYSE
- PLX Nasdaq
- Market Cap
- HPH 137.1M
- PLX 160.2M
- IPO Year
- HPH 2019
- PLX 1998
- Fundamental
- Price
- HPH $0.27
- PLX $2.22
- Analyst Decision
- HPH
- PLX
- Analyst Count
- HPH 0
- PLX 0
- Target Price
- HPH N/A
- PLX N/A
- AVG Volume (30 Days)
- HPH 142.5K
- PLX 553.9K
- Earning Date
- HPH 01-01-0001
- PLX 03-13-2025
- Dividend Yield
- HPH N/A
- PLX N/A
- EPS Growth
- HPH N/A
- PLX N/A
- EPS
- HPH N/A
- PLX N/A
- Revenue
- HPH $286,996,105.00
- PLX $45,667,000.00
- Revenue This Year
- HPH N/A
- PLX N/A
- Revenue Next Year
- HPH N/A
- PLX $90.00
- P/E Ratio
- HPH N/A
- PLX N/A
- Revenue Growth
- HPH 1722.42
- PLX N/A
- 52 Week Low
- HPH $0.23
- PLX $0.82
- 52 Week High
- HPH $10.06
- PLX $2.36
- Technical
- Relative Strength Index (RSI)
- HPH 39.75
- PLX 74.10
- Support Level
- HPH $0.23
- PLX $2.11
- Resistance Level
- HPH $0.29
- PLX $2.36
- Average True Range (ATR)
- HPH 0.05
- PLX 0.12
- MACD
- HPH -0.00
- PLX 0.00
- Stochastic Oscillator
- HPH 15.83
- PLX 77.42
About HPH HIGHEST PERFORMANCE HLDGS INC
Highest Performances Holdings Inc is a financial technology service group based on family financial asset allocation. It focuses on providing personalized wealth management services for emerging middle-class and affluent families, comprehensive support services for financial planners, and diversified financial services for institutional clients.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.